心肌缺血后处理胞内信号转导研究进展

缺血后处理对心肌再灌注损伤的保护是多因素参与的复杂过程。后处理对心肌的保护除了通过减少活性氧类物质的产生、抑制线粒体内钙超载、减轻内皮功能失调等被动作用外,还可主动激活再灌注损伤补救激酶（reperfusion injury salvage kinase,RISK）途径及其他蛋白激酶而实现。本文将对心肌缺血后处理中RISK通路的研究进展作一综述。     

腺苷和乙酰胆碱后适应诱导的心肌保护作用

近年来缺血后适应的提出成为抗再灌注损伤的里程碑,其良好的临床可控性和可靠的保护效应引起人们广泛关注。缺血后适应即在心肌长时间缺血后再灌注之前,进行数次短暂的再灌注,缺血的循环处理,诱导产生心肌保护效应,其循环次数和间隔时间存在种属差异。研究证实后适应不仅限制急性期梗死面积,还可以减轻长期损伤,其是否与保护血管内皮、抑制中性粒细胞介导的氧化损伤相关还存在争议。上调再灌注损伤补救激酶（reperfusion injury salvageHnase,RISK）通路是后适应保护的重要机制之一,即激活磷脂酰肌醇一3激酶（phosphatidy linositol3-kinase,P13K）-Akt途径和,或细胞外信号调节激酶（extracellular signal-regulatedkinase,ERK）途径,抑制线粒体通透性转换孔的开放,减少细胞凋亡和坏死。但是这两条途径的地位和关系还有待于进一步研究。为了更加适用于临床,研究者将机械调控转变为药物干预,观察药物能否模拟缺血后适应发挥保护作用,即药物后适应。腺苷是研究最广泛,也是最有希望成为临床正式用药的一种药物。我们实验室首先提出了乙酰胆碱可以模拟缺血后适应,通过线粒体ATP敏感钾通道发挥心肌保护效应。本文着重阐述缺血后适应保护缺血,再灌注损伤的效应和信号转导通路,尤其是腺苷和乙酰胆碱模拟药物后适应的可能机制和临床应用。     

线粒体通透性转换孔在缺血后处理中的作用和机制

心肌细胞急性缺血后,及时再灌注能够挽救缺血心肌细胞的活力、减少梗死面积、促进心肌细胞功能恢复。但是再灌注是一把“双刃剑”,它产生大量活性氧类（reactive oxygen species,ROS）和Ca2＋超载,开放线粒体通透性转换孔（mitochondrial permeability transition pore,mPTP）,使线粒体肿胀,外膜破裂导致心肌细胞坏死。mPTP是线粒体非特异性的转换孔,由电压依赖性阴离子通道（voltage-dependent anion channel,VDAC）、腺苷酸转位蛋白（adeninenucleotide translocator,ANT）和亲环蛋白D（cyclophilin D,CYPD）组成。mPTP关闭维持线粒体结构完整,是缺血心肌细胞功能恢复的先决条件。缺血后处理通过减少再灌注早期ROS大量释放和拮抗Ca^2＋超载、释放内源性介质、激活再灌注损伤补救激酶（reperfusion injury salvage kinase,RISK）、抑制mPTP开放,从而保护心肌细胞。     

缺血后处理内源性心脏保护的研究进展

再灌注疗法是临床治疗心肌缺血最有效的措施,但会引起再灌注损伤,调动机体内源性保护机制可以减轻再灌注损伤,保护缺血心肌。缺血预处理（ischemic preconditioning,IPC）和后处理（ischemic postconditioning,I-postC）是缺血心脏有效的内源性保护现象,可以减轻缺血再灌注（ischemia／reperfusion,I／R）后心肌坏死与心肌功能障碍,减少恶性心律失常的发生。内源性心脏保护的机制主要是通过诱导触发因子释放,经多条细胞内信号转导途径的介导,作用于多种效应器,影响氧自由基产生、钙超载等I／R损伤的关键环节而发挥心肌细胞保护作用。特别是可以在缺血后实施的I-postC具有良好的临床应用前景。本文以I-postC为重点综述内源性心脏保护作用、机制及其临床应用现状。     

活血化瘀注射液Ⅰ号对大鼠肝脏缺血再灌注损伤后P38 MAP kinase的表达情况影响研究

目的:研究活血化淤注射液Ⅰ号(HHI-Ⅰ)对肝脏缺血再灌注损伤后P38 MAP kinase的表达情况影响,为HHI-Ⅰ在临床防治肝缺血再灌注损伤的应用提供理论指导和技术支持。方法:清洁级健康雄性SD大鼠60只,体重250g左右,随机分为3组:假手术对照组(Ⅰ组)、缺血再灌注组(Ⅱ组)、HHI-Ⅰ预处理组(Ⅲ组),每组20只。分别建立大鼠肝脏缺血再灌注模型,免疫组织化学法测定肝脏缺血30min再灌注3h后组织中丝裂原活化蛋白激酶p38(P38 MAP kinase)的表达情况。结果:肝脏组织中P38 MAP kinase的表达Ⅱ、Ⅲ组高于Ⅰ组(P<0.05),Ⅲ组低于Ⅱ组(P<0.05)。结论:HHI-Ⅰ预处理可抑制P38 MAP kinase的表达,对大鼠肝脏缺血再灌注损伤有保护作用。     

Cariporide和还原型谷胱甘肽药物后适应对心肌缺血／再灌注损伤的保护作用

目的：观察钠氢交换阻断剂cariporide和抗氧化剂还原型谷胱甘肽（GSH）建立的药物后适应对心肌缺血／再灌注损伤的保护效应。方法：建立在体大鼠心肌缺血／再灌注模型,观察不同实验组间心梗面积和心肌酶学变化。结果：caripofide和GSH药物后适应可以减小心肌梗死面积,降低血浆磷酸肌酸激酶（CK）及丙二醛（MDA）的含量。结论：在心肌再灌注的开始,一次性给予钠氢交换阻断剂cariporide或抗氧化剂GSH,可减轻缺血／再灌注损伤,是两种有效的药物后适应干预。     

大剂量氨溴索对大鼠肺缺血再灌注损伤的保护作用及机制研究

目的：评价大剂量盐酸氨溴索（沐舒坦）对肺缺血再灌注损伤（Lungischemiareperfusioninjury,LIRI）的保护作用及其机制。方法：实验选取sD大鼠36只,分为三组：缺血再灌注损伤组;沐舒坦干预组;手术对照组。对大鼠进行左侧开胸并阻断左肺门根部60min,然后进行再灌注6h。沐舒坦干预组再灌注开始时,经股静脉持续6h输入沐舒坦溶液（3．75mg·kg-1．h-1）。分别检测大鼠动脉血氧分压,肺组织湿／干重比值,氧化应激因子（MDA,SOD,GSH-PX）含量,髓过氧化物酶（MPO）活力,细胞因子（TNF-α、MCP-1、TGF-β1）基因mRNA的表达水平,光镜下观察病理组织学改变。结果：（1）大剂量沐舒坦干预后,肺间质水肿、炎症细胞浸润、肺泡内出血、渗出等较再灌注损伤组明显改善（P〈O．05）;肺组织湿／干重比值显著降低（P〈0．05）;动脉血氧分压明显改善（P〈0．05）。（2）大剂量沐舒坦干预后,肺组织MDA、SOD、和GSH—PX含量基本降至正常水平;MPO活力降至手术对照组水平;差异均明显低于缺血再灌注损伤组（P〈0．05）。（3）沐舒坦干预组的TNF-α,MCP-1,TGF．B1基因mRNA表达水平在药物干预后虽未能恢复至正常水平,但是较缺血再灌注损伤组明显降低。结论：大剂量沐舒坦可参与下调肺组织的MDA、SOD、GSH．PX的含量和MPO活力,并通过下调TNF-α、MCP．1、TGF-β1基因rnRNA的表达水平达到减轻LIRI损伤程度的目的。本研究结果表明,沐舒坦通过调控uRJ在形成过程中相关基因的表达来抑制氧化应激损伤,从而有效的减轻肺缺血再灌注损伤。     

丹龙醒脑片对老年大鼠脑缺血再灌注后炎症反应的影响

目的:从肿瘤坏死因子-a(TNF-a)和白介素(IL-1β)表达变化揭示丹龙醒脑片抗老年脑缺血再灌注损伤的保护机制。方法:用大脑中动脉栓塞再通法建立脑缺血再灌注模型,将动物随机分为假手术组、模型组、丹龙醒脑片组和尼莫地平组,采用免疫组化法,观察TNF-a和IL-1β蛋白的表达。结果:丹龙醒脑片能显著减轻神经细胞的损伤;假手术组有一定量的TNF-a和IL-1β表达,缺血后TNF-a和IL-1β迅速增加,丹龙醒脑片组显著抑制TNF-a和IL-1β的表达,模型组和丹龙醒脑片组差异有统计学意义(P0.01,P0.05)。结论:丹龙醒脑片抗老年脑缺血再灌注损伤的保护机制与其抑制由缺血再灌注损伤诱导的TNF-a和IL-1β等表达有关。     

Eritoran对大鼠肾脏缺血再灌注损伤的保护作用

目的:观察eritoran对大鼠肾脏缺血再灌注损伤模型的.方法:建立SD大鼠缺血再灌注模型,给予eritoran治疗而对照组给予生理盐水治疗,观察各组的肾功能情况、肾组织光镜病理,并采用核糖核酸酶保护测定检测肾组织炎症因子/趋化因子的表达.结果:与模型组相比,eritoran预处理可显著改善大鼠的肾功能,减轻缺血再灌注引起的肾小管损伤,减轻肾组织病变,减少肾组织单核细胞浸润并下调多种炎症因子的表达(TNF-α,IL-6,IL-1β和MCP-1).结论:本研究证实通过eritoran抑制Toll样受体4,可减轻大鼠肾脏缺血再灌注损伤中的炎症反应,减轻肾脏缺血再灌注损伤,eritoran可望成为肾脏I/R损伤的新治疗手段.     

青霉胺对缺血后再灌注心肌损伤的保护作用

为了解青霉胺对缺血后再灌注心肌损伤的影响,我们采用Ｌａｎｇｅｎｄｒｏｆ离体大鼠心脏灌注模型,先灌注１５ｍｉｎ后停止灌注,模拟缺血６０ｍｉｎ,然后再灌注６０ｍｉｎ。动物分为对照组及青霉胺处理组（３０ｍＭ）。分别测定缺血前及再灌注后心肌组织内三磷酸腺苷（ＡＴＰ）、谷胱甘肽（ＧＳＨ）及谷胱甘肽氧化酶（ＧＳＨ－Ｐｘ）的含量变化,再灌注过程中冠状动脉血流阻力及冠脉流出液中磷酸肌酸激酶（ＣＰＫ）的释放量。结果显示,青霉胺处理组再灌注后心肌组织的ＡＴＰ、ＧＳＨ、ＧＳＨ－Ｐｘ含量均明显高于对照心肌组织中的含量,而青霉胺处理组在再灌注过程中ＣＰＫ的总释放量及平均冠状血流动脉阻力明显低于对照组ＣＰＫ总释放量及平均冠状动脉血流阻力。提示青霉胺可以减轻缺血后再灌注的心肌的损伤,起到保护作用     

中药抗心肌缺血再灌注损伤的信号通路研究进展

冠心病发生率、致死率高,严重危害人类健康。心肌缺血再灌注损伤是加重心肌损伤的主要病理机制,干预再灌注损伤挽救激酶、 单磷酸腺苷激酶、蛋白激酶 C 等信号传导通路保护心肌,成为减轻心肌损伤的重要途径之一。综述近 3 年国际期刊收录的中药有效成分、 提取物及复方制剂调节相关信号传导通路, 减轻心肌再灌注损伤的研究进展, 以期为阐释中药的作用特点, 有效防治心血管疾病提供参考。     

Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium

Intracellular signal transduction events in reperfusion following ischemia influence myocardial infarct development. Here we investigate the role of Rho kinase (ROCK) activation as a specific injury signal during reperfusion via attenuation of the reperfusion injury salvage kinase (RISK) pathway phosphatidylinositol 3-kinase (PI3K)/Akt/endothelial nitric oxide (NO) synthase (eNOS). Rat isolated hearts underwent 35 min of left coronary artery occlusion and 120 min of reperfusion. Phosphorylation of the ROCK substrate protein complex ezrin-radixin-moesin, assessed by immunoblotting and immunofluorescence, was used as a marker of ROCK activation. Infarct size was determined by tetrazolium staining, and terminal dUTP nick-end labeling (TUNEL) positivity was used as an index of apoptosis. The ROCK inhibitors fasudil or Y-27632 given 10 min before ischemia until 10 min after reperfusion reduced infarct size (control, 34.1 +/- 3.8%; 5 microM fasudil, 18.2 +/- 3.1%; 0.3 microM Y-27632, 19.4 +/- 4.4%; 5 microM Y-27632, 9.2 +/- 2.9%). When 5 microM Y-27632 was targeted specifically during early reperfusion, robust infarct limitation was observed (14.2 +/- 2.6% vs. control 33.4 +/- 4.4%, P<0.01). The protective action of Y-27632 given at reperfusion was attenuated by wortmannin (29.2 +/- 6.1%) and N(omega)-nitro-L-arginine methyl ester (30.4 +/- 5.7%), confirming a protective mechanism involving PI3K/Akt/NO. Ezrin-radixin-moesin phosphorylation in risk zone myocardium confirmed early and sustained ROCK activation during reperfusion and its inhibition by Y-27632. Inhibition of ROCK activation at reperfusion reduced the proportion of TUNEL-positive nuclei in the infarcted region. In conclusion, ROCK activation occurs specifically during early reperfusion. Inhibition of ROCK at reperfusion onset limits infarct size through an Akt/eNOS-dependent mechanism, suggesting that ROCK activation at reperfusion may be deleterious through suppression of the RISK pathway.     

Synergic effects of NO and oxygen free radicals in the injury of ischemia-reperfused myocardium——ESR studies on NO free radicals generated from ischemia-reperfused myocardium

The ESR signal of NO bound to hemoglobin was detected during the ischemia-reperfusion of myocardium with low temperature ESR technique, and the synergic effects of NO and oxygen free radicals in the injury of the process were studied with this technique. Oxygen free radicals and NO bound to β-subunit of hemoglobin (β-NO complex) could be detected simultaneously in the ischemia-reperfused myocardium. Those signals could not be detected from the normal myocardium even in the presence of L-arginme. However, those signals could be detected and were dose-dependent with L-arginine in the ischemia-reperfused myocardiums and the signal could be suppressed with the inhibitor of NO synthetase, NG-nitro-L-arginine methylester (NAME). Measurement of the activities of lactate dehydrogenase (LDH) and creatine kinase (CK) in the coronary artery effluent of ischemia-reperfused heart showed that L-arginine at lower concentration (<1 mmol/L) could protect the heart from the ischemia-reperfusion injury but at higher con     

Urocortin protects the heart from reperfusion injury via upregulation of p42/p44 MAPK signaling pathway

Reperfusion of ischemic myocardium is essential for tissue salvage but paradoxically contributes to cell death. We hypothesized that activation of potential survival pathways such as p42/p44 MAPK may prevent lethal reperfusion injury. Urocortin is a peptide factor that affects the p42/p44 MAPK signaling pathway. Both isolated and in vivo rat heart models were used to examine the potential for urocortin to prevent reperfusion injury. Isolated rat hearts underwent 35-min regional ischemia and 2-h reperfusion, with urocortin perfused for 20 min from the onset of reperfusion. In the in vivo study, urocortin was administered as an intravenous bolus 3 min before reperfusion with a protocol of 25-min regional ischemia and 2-h reperfusion. Blockade of the p42/p44 MAPK pathway with the inhibitor PD-98059 was used in both models. Urocortin attenuated lethal reperfusion-induced injury both in vitro and in vivo via a p42/p44 MAPK-dependent mechanism. Furthermore, Western blot analysis demonstrated the ability of urocortin to directly upregulate this signaling pathway. In conclusion, we believe that the p42/p44 MAPK-dependent signaling pathway represents an important survival mechanism against reperfusion injury.     

beta1-Adrenoreceptor activation contributes to ischemia-reperfusion damage as well as playing a role in ischemic preconditioning

Protein kinase A (PKA) activation has been implicated in early-phase ischemic preconditioning. We recently found that during ischemia PKA activation causes inactivation of cytochrome-c oxidase (CcO) and contributes to myocardial damage due to ischemia-reperfusion. It may be that beta-adrenergic stimulation during ischemia via endogenous catecholamine release activates PKA. Thus beta-adrenergic stimulation may mediate both myocardial protection and damage during ischemia. The present studies were designed to determine the role of the beta(1)-adrenergic receptor (beta(1)-AR) in myocardial ischemic damage and ischemic preconditioning. Langendorff-perfused rabbit hearts underwent 30-min ischemia by anterior coronary artery ligation followed by 2-h reperfusion. Occlusion-reperfusion damage was evaluated by delineating the nonperfused volume of myocardium at risk and volume of myocardial necrosis after 2-h reperfusion. In some hearts ischemic preconditioning was accomplished by two 5-min episodes of global low-flow ischemia separated by 10 min before coronary occlusion-reperfusion. Orthogonal electrocardiograms were recorded, and coronary flow was monitored by a drip count. Three hearts from each experimental group were used to determine mitochondrial CcO and aconitase activities. Two-hour reperfusion after occlusion caused an additional decrease in CcO activity vs. that after 30-min occlusion alone. Blocking the beta(1)-AR during occlusion-reperfusion reversed CcO activity depression and preserved myocardium at risk for necrosis. Similarly, mitochondrial aconitase activity exhibited a parallel response after occlusion-reperfusion as well as for the other interventions. Furthermore, classic ischemic preconditioning had no effect on CcO depression. However, blocking the beta(1)-AR during preconditioning eliminated the cardioprotection. If the beta(1)-AR was blocked after preconditioning, the myocardium was preserved. Interestingly, in both of the latter cases the depression in CcO activity was reversed. Thus the beta(1)-AR plays a dual role in myocardial ischemic damage. Our findings may lead to therapeutic strategies for preserving myocardium at risk for infarction, especially in coronary reperfusion intervention.     

Reduction of infarct size by cell-permeable oxygen metabolite scavengers.

The timely restoration of blood flow to severely ischemic myocardium limits myocardial infarct size. However, experimental studies demonstrate that the myocardial salvage achieved is suboptimal because of additional injury that occurs during reperfusion, due in part to the generation of reactive oxygen metabolites. Initially, superoxide (O2-) was considered to be the central mediator of reperfusion injury. While there are several potential pathways of O2- generation in reperfused myocardium, O2- is poorly reactive toward tissue biomolecules. However, O2-, in the presence of redox-active metals such as iron, generates .OH or hydroxyl-like species that are highly reactive with cell constituents. Thus, while O2- may initiate reaction sequences leading to myocardial injury, it may not be the actual injurious agent. In vitro studies suggest that oxygen metabolite injury occurs at intracellular sites and involves iron-catalyzed processes. Consistent with this mechanism, extracellular oxygen metabolite scavengers have not convincingly reduced infarct size. However, treatment around the time of reperfusion, after ischemia is well established, with cell-permeable scavengers of .OH reduce infarct size. Results with these cell-permeable agents suggest that in the intact animal during regional ischemia and reperfusion, oxygen metabolite injury also occurs at intracellular sites. Cell-permeable scavenger agents are a promising class of drugs for potential clinical use, though further experimental and toxicologic studies are required.     

PKCbeta modulates ischemia-reperfusion injury in the heart

Protein kinase C-betaII (PKCbetaII) is an important modulator of cellular stress responses. To test the hypothesis that PKCbetaII modulates the response to myocardial ischemia-reperfusion (I/R) injury, we subjected mice to occlusion and reperfusion of the left anterior descending coronary artery. Homozygous PKCbeta-null (PKCbeta(-/-)) and wild-type mice fed the PKCbeta inhibitor ruboxistaurin displayed significantly decreased infarct size and enhanced recovery of left ventricular (LV) function and reduced markers of cellular necrosis and serum creatine phosphokinase and lactate dehydrogenase levels compared with wild-type or vehicle-treated animals after 30 min of ischemia followed by 48 h of reperfusion. Our studies revealed that membrane translocation of PKCbetaII in LV tissue was sustained after I/R and that gene deletion or pharmacological blockade of PKCbeta protected ischemic myocardium. Homozygous deletion of PKCbeta significantly diminished phosphorylation of c-Jun NH(2)-terminal mitogen-activated protein kinase and expression of activated caspase-3 in LV tissue of mice subjected to I/R. These data implicate PKCbeta in I/R-mediated myocardial injury, at least in part via phosphorylation of JNK, and suggest that blockade of PKCbeta may represent a potent strategy to protect the vulnerable myocardium.